Stellar Biotechnologies Company Profile (NASDAQ:SBOT)

About Stellar Biotechnologies (NASDAQ:SBOT)

Stellar Biotechnologies logoStellar Biotechnologies, Inc. is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases. The Company's core business is developing and commercializing Keyhole Limpet Hemocyanin for use in immunotherapy and immunodiagnostic applications. The Company's Stellar KLH product offerings include Stellar KLH protein for conjugation and as carrier molecule in immunotherapy development; Stellar KLH protein and enzyme-linked immunosorbent assay (ELISA) test kits for immune function testing, and Custom KLH formulations, adjuvants, conjugations and fill finishes for preclinical research and drug development applications.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $11.89 million
  • Outstanding Shares: 10,520,000
Average Prices:
  • 50 Day Moving Avg: $1.20
  • 200 Day Moving Avg: $1.33
  • 52 Week Range: $1.05 - $3.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.97
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $501,509.00
  • Price / Sales: 23.70
  • Book Value: $0.82 per share
  • Price / Book: 1.38
Profitability:
  • EBIDTA: ($4,990,000.00)
  • Net Margins: -1,025.65%
  • Return on Equity: -49.68%
  • Return on Assets: -47.30%
Debt:
  • Current Ratio: 19.31%
  • Quick Ratio: 18.98%
Misc:
  • Average Volume: 21,397 shs.
  • Beta: 0.42
  • Short Ratio: 2.06
 

Frequently Asked Questions for Stellar Biotechnologies (NASDAQ:SBOT)

What is Stellar Biotechnologies' stock symbol?

Stellar Biotechnologies trades on the NASDAQ under the ticker symbol "SBOT."

How were Stellar Biotechnologies' earnings last quarter?

Stellar Biotechnologies, Inc. (NASDAQ:SBOT) posted its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.12) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.12). The firm earned $0.02 million during the quarter, compared to analysts' expectations of $0.34 million. Stellar Biotechnologies had a negative return on equity of 49.68% and a negative net margin of 1,025.65%. View Stellar Biotechnologies' Earnings History.

When will Stellar Biotechnologies make its next earnings announcement?

Stellar Biotechnologies is scheduled to release their next quarterly earnings announcement on Tuesday, December, 12th 2017. View Earnings Estimates for Stellar Biotechnologies.

Where is Stellar Biotechnologies' stock going? Where will Stellar Biotechnologies' stock price be in 2017?

1 equities research analysts have issued 1-year target prices for Stellar Biotechnologies' shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Stellar Biotechnologies' stock price to reach $4.00 in the next year. View Analyst Ratings for Stellar Biotechnologies.

Who are some of Stellar Biotechnologies' key competitors?

Who are Stellar Biotechnologies' key executives?

Stellar Biotechnologies' management team includes the folowing people:

  • Frank R. Oakes, Chairman of the Board, President, Chief Executive Officer
  • Kathi Niffenegger CPA, Chief Financial Officer, Secretary
  • Gregory T. Baxter Ph.D., Executive Vice President - Corporate Development
  • Tessie Mary Che Ph.D., Director
  • Paul Chun, Director
  • Daniel E. Morse Ph.D., Director
  • Charles Olson, Director
  • David L. Hill Ph.D., Independent Director

How do I buy Stellar Biotechnologies stock?

Shares of Stellar Biotechnologies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Stellar Biotechnologies' stock price today?

One share of Stellar Biotechnologies stock can currently be purchased for approximately $1.13.


MarketBeat Community Rating for Stellar Biotechnologies (NASDAQ SBOT)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  47 (Vote Outperform)
Underperform Votes:  21 (Vote Underperform)
Total Votes:  68
MarketBeat's community ratings are surveys of what our community members think about Stellar Biotechnologies and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Stellar Biotechnologies (NASDAQ:SBOT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.00 (253.98% upside)

Analysts' Ratings History for Stellar Biotechnologies (NASDAQ:SBOT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
12/2/2016Maxim GroupLower Price TargetBuy$7.00 -> $4.00N/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for Stellar Biotechnologies (NASDAQ:SBOT)
Earnings by Quarter for Stellar Biotechnologies (NASDAQ:SBOT)
Earnings History by Quarter for Stellar Biotechnologies (NASDAQ SBOT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
12/12/2017($0.11)N/AView Earnings Details
8/9/2017Q3 2017($0.12)($0.12)$0.34 million$0.02 millionViewN/AView Earnings Details
5/9/2017Q2 2017($0.15)($0.11)$0.33 million$0.06 millionViewN/AView Earnings Details
2/6/2017Q1 2017($0.10)($0.15)$0.31 million$0.14 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Stellar Biotechnologies (NASDAQ:SBOT)
2017 EPS Consensus Estimate: ($0.60)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.18)($0.18)($0.18)
Q2 20171($0.15)($0.15)($0.15)
Q3 20171($0.14)($0.14)($0.14)
Q4 20171($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Stellar Biotechnologies (NASDAQ:SBOT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Stellar Biotechnologies (NASDAQ:SBOT)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Stellar Biotechnologies (NASDAQ:SBOT)
Latest Headlines for Stellar Biotechnologies (NASDAQ:SBOT)
Source:
DateHeadline
finance.yahoo.com logoSBOT: Neovacs Ph 2 Lupus Study Completes Enrollment. Read-Out Q2 2018
finance.yahoo.com - September 6 at 8:00 AM
finance.yahoo.com logoStellar Biotechnologies, Inc. :SBOT-US: Earnings Analysis: Q3, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 11:22 AM
americanbankingnews.com logoStellar Biotechnologies, Inc. (SBOT) Releases Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - August 10 at 11:28 PM
prnewswire.com logoStellar Biotechnologies Reports Third Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - August 10 at 8:20 PM
finance.yahoo.com logoStellar Biotechnologies Reports Third Quarter 2017 Financial Results
finance.yahoo.com - August 10 at 7:41 AM
americanbankingnews.com logoStellar Biotechnologies, Inc. (NASDAQ:SBOT) to Release Earnings on Monday
www.americanbankingnews.com - July 31 at 11:40 AM
prnewswire.com logoStellar Biotechnologies Expands Operations Team - PR Newswire (press release)
www.prnewswire.com - June 8 at 3:00 AM
finance.yahoo.com logoStellar Biotechnologies Expands Operations Team
finance.yahoo.com - June 8 at 3:00 AM
finance.yahoo.com logoStellar Biotechnologies, Inc. :SBOT-US: Earnings Analysis: Q2, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 11:49 PM
finance.yahoo.com logoStellar Biotechnologies to Present at Marcum Investor Conference
finance.yahoo.com - May 31 at 12:38 PM
finance.yahoo.com logoSBOT: Clinical Trial Progression Remains Key Metric
finance.yahoo.com - May 27 at 4:16 AM
americanbankingnews.com logoStellar Biotechnologies Inc (SBOT) Posts Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - May 10 at 6:40 PM
prnewswire.com logoStellar Biotechnologies Reports Second Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - May 10 at 11:02 AM
americanbankingnews.com logoStellar Biotechnologies (SBOT) Earns Daily News Sentiment Rating of 0.08
www.americanbankingnews.com - May 1 at 5:36 PM
americanbankingnews.com logoStellar Biotechnologies (SBOT) Earning Positive Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 28 at 6:50 PM
americanbankingnews.com logoStellar Biotechnologies (SBOT) Receives Daily News Impact Rating of 0.33
www.americanbankingnews.com - April 22 at 12:55 PM
biz.yahoo.com logoSTELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to
biz.yahoo.com - March 29 at 8:32 AM
streetinsider.com logoStellar Biotechnologies (SBOT) to Sell 'Immunogen & Vaccine Technology' to Matrivax
www.streetinsider.com - March 13 at 7:24 PM
us.rd.yahoo.com logoStellar Biotechnologies and Matrivax Sign Agreement to Transfer Vaccine Technology
us.rd.yahoo.com - March 13 at 7:24 PM
biz.yahoo.com logoSTELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Other Events, Finan
biz.yahoo.com - March 13 at 7:24 PM
finance.yahoo.com logoThe Life Sciences Report Examines Stellar Biotechnologies (SBOT:NASDAQ) Inking Multiyear KLH Supply Agreement with Amaran Biotechnology; Stellar Up 27% on News
finance.yahoo.com - March 6 at 11:51 AM
finance.yahoo.com logoAmaran Biotechnology Selects Stellar KLH for Cancer Vaccines - Yahoo Finance
finance.yahoo.com - March 4 at 12:44 AM
prnewswire.com logoAmaran Biotechnology Selects Stellar KLH for Cancer Vaccines - PR Newswire (press release)
www.prnewswire.com - March 2 at 1:02 AM
us.rd.yahoo.com logoAmaran Biotechnology Selects Stellar KLH for Cancer Vaccines
us.rd.yahoo.com - March 1 at 10:06 AM
finance.yahoo.com logoSBOT: Q1 Light On Revenue But Clinical Trial Progression Suggests Growth Ahead
finance.yahoo.com - February 10 at 2:12 AM
prnewswire.com logoStellar Biotechnologies Reports First Quarter 2017 Financial Results - PR Newswire (press release)
www.prnewswire.com - February 7 at 8:08 AM
us.rd.yahoo.com logo8:24 am Stellar Biotechnologies issues a statement congratulating Neovacs S.A. for its decision to extend the development of its lupus drug for Type 1 diabetes
us.rd.yahoo.com - February 7 at 12:53 AM
finance.yahoo.com logoStellar Biotechnologies Reports First Quarter 2017 Financial Results
finance.yahoo.com - February 6 at 7:49 PM
finance.yahoo.com logoStellar Biotechnologies Congratulates Partner's Decision to Extend Drug Development for Diabetes
finance.yahoo.com - February 6 at 8:34 AM
finance.yahoo.com logo7:31 am Stellar Biotechnologies to expand production of its Stellar KLH products under a recently established Mexican subsidiary
finance.yahoo.com - January 11 at 10:27 PM
finance.yahoo.com logoStellar Biotechnologies to Present at Biotech Showcase Conference
finance.yahoo.com - January 5 at 6:29 AM
finance.yahoo.com logoSBOT: 2016 A Solid Year, Both Financially and Operationally
finance.yahoo.com - December 20 at 2:33 PM
finance.yahoo.com logoSTELLAR BIOTECHNOLOGIES, INC. Financials
finance.yahoo.com - December 20 at 2:33 PM
finance.yahoo.com logoStellar Biotechnologies Reports Fiscal Year 2016 Financial Results
finance.yahoo.com - December 14 at 10:01 PM
biz.yahoo.com logoSTELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
biz.yahoo.com - December 14 at 10:01 PM
finance.yahoo.com logoStellar Biotechnologies Announces Fiscal Year 2016 Corporate Update Conference Call
finance.yahoo.com - December 12 at 9:17 AM
biz.yahoo.com logoSTELLAR BIOTECHNOLOGIES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial
biz.yahoo.com - December 9 at 7:36 PM

Social

Chart

Stellar Biotechnologies (SBOT) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff